HUE048925T2 - CTLA-4 variánsok - Google Patents

CTLA-4 variánsok

Info

Publication number
HUE048925T2
HUE048925T2 HUE17163638A HUE17163638A HUE048925T2 HU E048925 T2 HUE048925 T2 HU E048925T2 HU E17163638 A HUE17163638 A HU E17163638A HU E17163638 A HUE17163638 A HU E17163638A HU E048925 T2 HUE048925 T2 HU E048925T2
Authority
HU
Hungary
Prior art keywords
ctla
variants
Prior art date
Application number
HUE17163638A
Other languages
English (en)
Hungarian (hu)
Inventor
Ralph Minter
Julie Douthwaite
Jacques Moisan
Michael Bowen
Steven Rust
Cyril Privesentzev
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of HUE048925T2 publication Critical patent/HUE048925T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/425Zeins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02EREDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00Technologies for the production of fuel of non-fossil origin
    • Y02E50/10Biofuels, e.g. bio-diesel

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE17163638A 2012-05-11 2013-03-11 CTLA-4 variánsok HUE048925T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261645686P 2012-05-11 2012-05-11

Publications (1)

Publication Number Publication Date
HUE048925T2 true HUE048925T2 (hu) 2020-09-28

Family

ID=49551120

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17163638A HUE048925T2 (hu) 2012-05-11 2013-03-11 CTLA-4 variánsok

Country Status (17)

Country Link
US (2) US9884902B2 (cg-RX-API-DMAC7.html)
EP (2) EP3207938B1 (cg-RX-API-DMAC7.html)
JP (1) JP6228971B2 (cg-RX-API-DMAC7.html)
KR (1) KR102133060B1 (cg-RX-API-DMAC7.html)
CN (2) CN107540742B (cg-RX-API-DMAC7.html)
AU (1) AU2013260172B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014026718B1 (cg-RX-API-DMAC7.html)
CA (1) CA2868748C (cg-RX-API-DMAC7.html)
DK (1) DK3207938T3 (cg-RX-API-DMAC7.html)
ES (1) ES2777778T3 (cg-RX-API-DMAC7.html)
HK (1) HK1209644A1 (cg-RX-API-DMAC7.html)
HU (1) HUE048925T2 (cg-RX-API-DMAC7.html)
MX (2) MX385969B (cg-RX-API-DMAC7.html)
PL (1) PL3207938T3 (cg-RX-API-DMAC7.html)
RU (1) RU2671465C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201609447XA (cg-RX-API-DMAC7.html)
WO (1) WO2013169338A1 (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119857A1 (de) 1991-06-17 1992-12-24 Basf Lacke & Farben Ueberzugsmittel auf der basis von carboxylgruppenhaltigen polymeren und epoxidharzen
RU2671465C2 (ru) * 2012-05-11 2018-10-31 Медиммьюн Лимитед Варианты ctla-4
PL2867251T3 (pl) * 2012-06-29 2020-03-31 Bristol-Myers Squibb Company Sposoby zmniejszania agregacji glikoprotein
WO2014138188A1 (en) * 2013-03-07 2014-09-12 The General Hospital Corporation Human ctla4 mutants and use thereof
CN105916883B (zh) * 2014-01-28 2019-12-03 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
EP3244907B1 (en) * 2015-01-13 2020-02-19 City of Hope Ctla4-binding protein peptide-linker masks
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US11351224B2 (en) 2015-08-21 2022-06-07 Iucf-Hyu (Industry-University Cooperation Foundation Hanyang University) Pharmaceutical composition for preventing and treating transplant rejection
CN108137659B (zh) 2015-08-21 2021-11-26 汉阳大学校产学协力团 具有预防或治疗中枢神经系统疾病作用的肽和包含其作为活性成分的药物组合物
WO2017034244A1 (ko) * 2015-08-21 2017-03-02 한양대학교 산학협력단 중추신경계 질환에 대한 예방 또는 치료효과를 갖는 펩타이드 및 이를 유효성분으로 하는 중추신경계 질환 예방 및 치료용 약학적 조성물
JP2018534245A (ja) * 2015-09-14 2018-11-22 アルパイン イミューン サイエンシズ インコーポレイテッド 調整可能なバリアント免疫グロブリンスーパーファミリードメインおよび改変細胞療法
MA44082A (fr) 2015-12-14 2018-10-24 Macrogenics Inc Molécules bispécifiques présentant une immunoréactivité par rapport à pd-1 et à ctla-4 et leurs procédés d'utilisation
KR101918456B1 (ko) * 2015-12-15 2018-11-16 앱클론(주) Cd80 및 cd86에 특이적으로 결합하는 항체
KR20190006495A (ko) 2016-04-15 2019-01-18 알파인 이뮨 사이언시즈, 인코포레이티드 Cd80 변이체 면역조절 단백질 및 그의 용도
KR20230051602A (ko) 2016-04-15 2023-04-18 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
WO2018170026A2 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
RU2022108410A (ru) 2017-05-24 2022-04-05 ЭйЭлЭс ТЕРАПИ ДЕВЕЛОПМЕНТ ИНСТИТЬЮТ Терапевтические антитела против лиганда cd40
KR102813968B1 (ko) * 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
SG11202003078VA (en) 2017-10-18 2020-05-28 Alpine Immune Sciences Inc Variant icos ligand immunomodulatory proteins and related compositions and methods
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2020088645A1 (en) 2018-11-02 2020-05-07 Beijing Vdjbio Co., Ltd. Modified ctla4 and methods of use thereof
WO2020210596A1 (en) * 2019-04-10 2020-10-15 University Of Kentucky Research Foundation Modified prostate apoptosis response-4 (par-4) polypeptide, and methods of production and use
CA3166299A1 (en) * 2020-01-11 2021-07-15 Paul STABACH Compositions and methods for treating, ameliorating, and/or preventing diseases or disorders caused by or associated with dnase1 and/or dnase1l3 deficiency
EP4045533B1 (en) 2020-03-26 2023-11-15 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
CA3171795A1 (en) * 2020-04-06 2021-10-14 Jintang DU Modular synthetic receptors and methods of use
EP4142792A4 (en) 2020-05-01 2024-11-27 Kashiv Biosciences, LLC An improved process of purification of protein
CN112661865A (zh) * 2020-12-31 2021-04-16 厚朴生物科技(苏州)有限公司 针对新型冠状病毒的疫苗以及其应用
US20250236640A1 (en) * 2021-10-08 2025-07-24 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
CA3234496A1 (en) * 2021-10-08 2023-04-13 Kashiv Biosciences, Llc Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
CA3242952A1 (en) * 2021-12-17 2025-04-29 Kashiv Biosciences, Llc IMPROVED DOSAGE METHOD FOR DETERMINING THE POTENCY OF A RECOMBINATING PROTEIN
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
WO2024211211A1 (en) 2023-04-03 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661854B2 (en) 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
JP2000515731A (ja) * 1996-06-14 2000-11-28 スミスクライン・ビーチャム・コーポレイション 6量体融合タンパク質およびその使用
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02011534A (es) * 2000-05-26 2004-08-12 Bristol Myers Squibb Co Moleculas mutantes ctla4 solubles y uso de las mismas.
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
JP4784772B2 (ja) 2005-07-07 2011-10-05 東芝ライテック株式会社 放電灯点灯装置および電球形蛍光ランプ
GB0620934D0 (en) * 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
EP2222697B1 (en) * 2007-11-01 2012-12-05 Perseid Therapeutics LLC Immunosuppressive polypeptides and nucleic acids
PT3053932T (pt) * 2010-02-19 2020-10-21 Xencor Inc Novas imunoadesinas ctla4-ig
KR20130049775A (ko) * 2010-03-12 2013-05-14 애브비 바이오테라퓨틱스 인크. Ctla4 단백질 및 이의 용도
RU2671465C2 (ru) * 2012-05-11 2018-10-31 Медиммьюн Лимитед Варианты ctla-4

Also Published As

Publication number Publication date
CA2868748C (en) 2022-07-26
KR20150014443A (ko) 2015-02-06
PL3207938T3 (pl) 2020-07-13
KR102133060B1 (ko) 2020-07-10
AU2013260172B2 (en) 2017-11-23
US20150104450A1 (en) 2015-04-16
RU2671465C2 (ru) 2018-10-31
SG11201405968SA (en) 2014-11-27
MX355234B (es) 2018-04-11
EP3207938A3 (en) 2017-11-01
CN107540742A (zh) 2018-01-05
BR112014026718A2 (pt) 2017-07-18
HK1209644A1 (en) 2016-04-08
SG10201609447XA (en) 2017-01-27
WO2013169338A1 (en) 2013-11-14
MX385969B (es) 2025-03-18
JP6228971B2 (ja) 2017-11-08
CN107540742B (zh) 2021-06-29
EP2863936A1 (en) 2015-04-29
AU2013260172A1 (en) 2014-10-23
EP2863936A4 (en) 2016-10-05
US9884902B2 (en) 2018-02-06
MX2014013092A (es) 2015-03-03
CN104302309B (zh) 2017-07-28
ES2777778T3 (es) 2020-08-06
RU2014150092A (ru) 2016-07-10
US20180208639A1 (en) 2018-07-26
DK3207938T3 (da) 2020-03-16
CA2868748A1 (en) 2013-11-14
EP3207938A2 (en) 2017-08-23
CN104302309A (zh) 2015-01-21
EP3207938B1 (en) 2019-12-25
JP2015523328A (ja) 2015-08-13
BR112014026718B1 (pt) 2021-05-18

Similar Documents

Publication Publication Date Title
NL301231I2 (nl) Loncastuximab tesirine
FIC20230011I1 (fi) Farisimabi
NL301173I2 (nl) amivantamab
NO2022024I1 (no) Roxadustat
NL301141I2 (nl) duvelisib
NL301107I2 (nl) inclisiran
DK3207938T3 (da) Ctla-4-varianter
EP2763896A4 (en) UNMANUFACTURED AIRCRAFT WITH SEVERAL ROTORS
DK2859055T3 (da) Polymercoatings
EP2880683A4 (en) BVA INTERPOSER
DK2825087T3 (da) Otoscanner
EP2809145A4 (en) CHLOROPLAST TRANSIT PEPTIDES
EP2814472A4 (en) DITHIOAMINE REDUCING AGENTS
DK2839013T3 (da) Ikke-disruptiv-gen-targetering
EP2824794A4 (en) Charging cable
EP2847405A4 (en) DOOR CLOSURE SYSTEM
EP2805877A4 (en) UNDER HOOD
DE112012006109A5 (de) Okklusionsschienenanordnung
DK2873977T3 (da) Dobbeltdækker-rørdispenser
DK2854722T3 (da) Stomipose
EP2941099A4 (en) SWITCHING DEVICE
EP2831482A4 (en) Flange gasket
EP2816694A4 (en) FLAT CABLE WINDING DEVICE
DK2825157T3 (da) Aminosyrelipider
EP2809729A4 (en) Siloxane polyether copolymers